Joshi Krishna C, Kolb Bradley, Khalili Bobak F, Munich Stephan A, Byrne Richard W
Department of Neurosurgery, Rush University Medical Center, Chicago , Illinois , USA.
Rush Medical College, Chicago , Illinois , USA.
Oper Neurosurg. 2024 Jan 1;26(1):4-15. doi: 10.1227/ons.0000000000000896. Epub 2023 Sep 1.
The management of giant pituitary adenomas (GPAs) is challenging due to associated endocrinopathies and the close proximity of these tumors to critical structures, such as the optic nerves, structures of the cavernous sinus, and hypothalamus. The objective of this review article was to summarize the current management strategies for giant pituitary adenomas, including the role of open and endoscopic surgical approaches and the role of medical and radiation therapy in conjunction with surgery.
We conducted a retrospective review of GPAs operated at our institute between January 2010 and March 2023. Surgical approaches, extent of resection, and associated complications were documented. Furthermore, we conducted a thorough literature review to identify relevant studies published in the past decade, which were incorporated along with insights gained from our institutional case series of GPAs to analyze and integrate both the existing knowledge base and our institution's firsthand experience in the management of GPAs.
A total of 46 giant pituitary adenomas (GPAs) were operated on, using various surgical approaches. Transsphenoidal approach was used in 25 cases and a staged approach using transsphenoidal and pterional was used in 15 cases. Other approaches included transcortical-transventricular, transcallosal, pterional/orbitozygomatic, and subfrontal approaches. Complications and technical nuances were reported.
The management of giant pituitary adenomas remains complex, often involving several modalities-open or endoscopic resection, radiosurgery, and medical management of both the tumor and associated endocrinopathies. Surgical resections are often challenging procedures that require careful consideration of several factors, including patient characteristics, tumor location, and size, and the experience and skill of the surgical team.
巨大垂体腺瘤(GPA)的治疗具有挑战性,因为其伴有内分泌疾病,且这些肿瘤与关键结构(如视神经、海绵窦结构和下丘脑)距离很近。这篇综述文章的目的是总结巨大垂体腺瘤的当前治疗策略,包括开放手术和内镜手术方法的作用以及药物治疗和放射治疗与手术联合应用的作用。
我们对2010年1月至2023年3月在我院接受手术的巨大垂体腺瘤进行了回顾性研究。记录了手术方法、切除范围和相关并发症。此外,我们进行了全面的文献综述,以确定过去十年发表的相关研究,并将这些研究与我们机构巨大垂体腺瘤病例系列中获得的见解相结合,以分析和整合现有的知识库以及我们机构在巨大垂体腺瘤治疗方面的第一手经验。
共对46例巨大垂体腺瘤进行了手术,采用了各种手术方法。25例采用经蝶窦入路,15例采用经蝶窦和翼点分期入路。其他入路包括经皮质-经脑室、经胼胝体、翼点/眶颧和额下入路。报告了并发症和技术细节。
巨大垂体腺瘤的治疗仍然很复杂,通常涉及多种方式——开放或内镜切除、放射外科以及对肿瘤和相关内分泌疾病的药物治疗。手术切除往往是具有挑战性的操作,需要仔细考虑几个因素,包括患者特征、肿瘤位置和大小,以及手术团队的经验和技能。